: david 
subject : medical news part 
: david 
distribution : world 
organization : stat gateway service , 
lines : 707 
------------- cut ----------------- 
volume 6 , number 11 april 25 , 1993 
+ ------------------------------------------------ + 
! 
! 
! 
health network ! 
! 
medical newsletter ! 
+ ------------------------------------------------ + 
editor : david , 
north 92nd street , suite 210 , scottsdale , arizona usa 
telephone +1 
fax +1 
compilation copyright 1993 david , rights reserve . 
license hereby grant republish electronic media 
fee charge , long text copyright notice license 
attach intact republish portion portion . 
health network newsletter distribute biweekly . 
articles 
medical nature welcome . 
article , please contact 
editor information submit . 
interested 
join automated distribution system , please contact editor . 
e-mail address : 
editor : 
internet : 
fidonet 15 
bitnet 
listserv internet : 
anonymous ftp . 

notification list 
fax delivery contact editor information 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
b l e o f c o n e n 
1 . 
centers disease control prevention - mmwr 
23 april 1993 rates cesarean delivery ... ... ... ... ... . 
. 
1 
malaria among u.s. embassy personnel ... ... ... ... ... ... ... 5 
fda approval hib vaccine ... ... ... ... . 
8 
2 . 
dental news 
workshop explore oral manifestation hiv infection ... ... ... 11 
3 . 
food & drug administration news 
fda approve depo provera , injectable contraceptive ... ... ... ... 14 
new rules speed approval drug life-threatening illness ... 16 
4 . 
articles 
research promise blindness retinal disease . 
. 
18 
affluent diet increase risk heart disease ... ... ... ... ... 20 
5 . 
general 
publications health professionals national cancer institute . 
23 
publications patients available national cancer institute ... 30 
6 . 
aids news summaries 
aids daily summary april 19 april 23 , 1993 ... ... ... ... 38 
7 . 
aids statistics 
worldwide aids statistics ... ... ... ... ... ... ... ... ... 48 
medical newsletter page 
volume 6 , number 11 april 25 , 1993 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
centers disease control prevention - mmwr 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
rate cesarean delivery -- united states , 1991 

source : mmwr 42 15 date : apr 23 , 1993 
cesarean delivery account nearly 1 million 
approximately 4 million annual delivery united states since 1986 
table 1 . 
cesarean rate united states third highest among 
21 report country , exceed brazil puerto rico 1 . 

report present datum cesarean delivery cdc 's national hospital 
discharge survey nhd 1991 compare datum previous year . 
datum discharge short-stay , nonfederal hospital 
collect annually since 1965 nhd , conduct cdc 's national center 
health statistics . 
1991 , medical demographic information 
abstract sample 274,000 inpatient discharge 484 
participate hospital . 
1991 cesarean vaginal birth prior 
cesarean vbac present report base weighted national 
estimate nhd sample approximately 31,000 11 % woman discharge 
delivery . 
estimated number live birth type delivery 
calculate apply cesarean rate nhd live birth 
national vital registration datum . 
therefore , estimate number 
cesarean report agree previously publish datum base 
solely nhd 2 . 
state difference analysis significant 
95 % confidence level , base two-tailed t-test critical value 
1.96 . 
1991 , 23.5 cesarean per 100 delivery , rate 
1990 similar rate 1986-1989 table 1 . 
primary cesarean 
rate i.e. , number first cesarean per 100 delivery woman 
previous cesarean 1986-1991 also stable , range 16.8 17.5 . 
1991 , cesarean rate south 27.6 , significantly p < 0.05 
higher rate west 19.8 , midwest 21.8 , northeast 
22.6 . 
rate higher mother aged greater equal 30 year 
younger woman ; proprietary hospital nonprofit 
government hospital ; hospital fewer 300 bed larger 
hospital ; delivery blue shield 
private insurance expect source payment source 
payment table 2 . 
pattern characterize primary cesarean delivery . 
since early 1970s , number percentage birth older woman 
increase ; however , age distribution mother 1991 remain 
1986 , overall cesarean rate 1991 would 23.3 , 
essentially 23.5 observe . 
base nhd , approximately live birth 1991 , 
medical newsletter page 1 
volume 6 , number 11 april 25 , 1993 
estimate 966,000 23.5 % cesarean delivery . 
, estimate 
338,000 35.0 % birth repeat cesarean , 628,000 65.0 % primary 
cesarean . 
since 1986 , approximately 600,000 primary cesarean 
perform annually . 
1986 , 8.5 % woman previous cesarean 
deliver vaginally , compare 24.2 % 1991 . 
cesarean 1991 , 
35.0 % associate previous cesarean , 30.4 % i.e. , 
failure labor progress , 11.7 % breech presentation , 9.2 % fetal 
distress , 13.7 % specify complication . 
average hospital stay delivery 1991 2.8 day . 

comparison , hospital stay primary cesarean delivery 4.5 day , 
repeat cesarean , 4.2 day -- nearly twice duration vbac 
delivery 2.2 day vaginal delivery vbac 2.3 
day . 
1986 , average hospital stay delivery 3.2 day , 
primary cesarean 5.2 day , repeat cesarean 4.7 day , vbac 
vaginal delivery 2.7 2.6 day , respectively . 
report : office vital health statistics systems , national center 
health statistics , cdc . 
editorial note : cesarean rate united states steadily increase 
1965 1986 ; however , finding report indicate rate 
stable since 1986 3 . 
little evidence 
maternal child health status improve time 
cesarean associate increase risk complication 
childbirth , national health objective year 2000 4 reduce 
overall cesarean rate 15 fewer per 100 delivery primary 
cesarean rate 12 fewer per 100 delivery objective 14.8 . 
postpartum complication -- include urinary tract wound infection 
-- may account part longer hospital stay cesarean delivery 
vaginal birth 5 . 
moreover , prolonged hospital stay 
cesarean delivery substantially increase health-care cost . 
example , 
1991 , average cost cesarean vaginal delivery $ 
$ , respectively . 
additional cost cesarean delivery include 
$ 611 physician fee $ 2495 hospital charge 6 . 
cesarean 
rate 1991 15 year 2000 objective instead 23.5 , number 
cesarean birth would decrease 349,000 617,000 versus 966,000 , 
result savings $ 1 billion physician fee hospital 
charge . 
despite steady increase vbac rate since 1986 , several factor may 
impede progress toward year 2000 national health objective cesarean 
delivery . 
example , vbac rate substantially reflect number woman 
offer trial labor , increasingly encouraged since 1982 7 . 
woman offer trial labor , 50 % -70 % could deliver vaginally 7 
-- level already achieve many hospital 8 . 
trial labor routinely 
offer 46 % hospital survey 1984 recent year 
medical newsletter page 2 
volume 6 , number 11 april 25 , 1993 
national datum available 9 vbac rate accord nhd datum 
5.7 % . 
year 2000 objective specify vbac rate 35 % , base 
woman prior cesarean , regardless whether trial labor 
attempt . 
reach overall cesarean rate goal , however , increase 
vbac rate need combine substantial reduction primary 
rate . 
one hospital succeed reduce rate cesarean delivery 
apply objective criterion four common indication cesarean 
delivery , require second opinion , institute peer-review 
process 10 . 
recommendation decrease cesarean delivery rate 
include eliminate incentive physician hospital equalize 
reimbursement vaginal cesarean delivery ; public dissemination 
physician - cesarean delivery rate increase public 
awareness difference practice ; address malpractice concern , 
may important factor maintain high rate cesarean 
delivery 4 . 
reference 
1 . 
fc . 
international difference use obstetric intervention . 
jama 1990 ; -91 . 
2 . 
graves ej , nchs . 
1991 summary : national hospital discharge survey . 
hyattsville , maryland : us department health human services , public 
health service , cdc , 1993 . 
advance datum no. 227 . 
3 . 
taffel sm , placek pj , cl . 
u.s. cesarean section rate , 1990 : 
update . 
birth 1992 ; 19:21 -2 . 
4 . 
public health service . 
healthy people 2000 : national health promotion 
disease prevention objective -- full report , commentary . 
washington , dc : 
us department health human services , public health service , 1991 ; 
publication . 
ph . 
5 . 
danforth dn . 
cesarean section . 
jama 1985 ; -8 . 
6 . 
hospital insurance association america . 
table 4.15 : cost maternity 
care , physician ' fee , hospital charge , census region , base 
consumer price index 1991 . 
: 1992 source book health insurance datum . 
washington , dc : hospital insurance association america , 1992 . 
7 . 
committee obstetrics . 
acog committee opinion no. 64 : guideline 
vaginal delivery previous cesarean birth . 
washington , dc : american 
college obstetricians gynecologists , 1988 . 
medical newsletter page 3 
volume 6 , number 11 april 25 , 1993 
8 . 
rosen mg , dickinson jc . 
vaginal birth cesarean : meta-analysis 
indicator success . 
1990 ; -9 . 
9 . 
ph , fielden jg , d , rhoads gg , pearse wh . 
recent trend 
cesarean birth trial labor rate united states . 
jama 
1987 ; -7 . 
10 . 
myers sa , gleicher n. successful program lower 
rate . 
n engl j med 1988 ; -6 . 
use trade name commercial source identification 
imply endorsement public health service u.s. department 
health human services . 
medical newsletter page 4 
volume 6 , number 11 april 25 , 1993 
malaria among u.s. embassy personnel -- kampala , uganda , 1992 

source : mmwr 42 15 date : apr 23 , 1993 
treatment prevention malaria africa become 
challenging complex problem increase drug resistance . 
although risk acquire malaria u.s. citizen dependent 
station overseas generally low , risk vary substantially 
unpredictably . 
may 1992 , office medical services , department 
state , cdc notify increase number malaria case 
among official u.s. personnel station kampala , uganda . 
review 
health record embassy health unit kampala indicate 27 
case malaria diagnose official personnel march june 
1992 compare two case period 1991 . 
, , 
cdc conduct investigation confirm report malaria case 
identify potential risk factor malaria among u.s. embassy personnel . 

report summarize result investigation . 
malaria blood smear 25 27 report 
available review cdc . 
case malaria confirm 
slide positive plasmodium sp . 
25 person , 17 slide - 
confirm malaria . 
questionnaire distribute person serve 
obtain information residence , activity , use malaria 
, use personal protection measure i.e. , use 
insect repellent , window door screen , wear long 
sleeve pants evening . 
157 person eligible survey , 
128 82 % respond . 
risk malaria associate sex location residence 
kampala . 
although risk malaria higher among child age less 
equal 15 year 19 % among person greater 15 
year 12 % , difference significant relative risk 
rr 1.6 ; 95 % confidence interval ci .0 . 
eighty-two percent 
case occur among person live kampala 1-5 year , 
compare live less 1 year . 
travel outside 
kampala area rural setting associate increase risk 
malaria . 
four malaria regimen use person 
participate survey : mefloquine , chloroquine , chloroquine 
alone , alone . 
addition , 23 18 % person respond 
use malaria . 
risk malaria significantly 
lower among person use either mefloquine chloroquine 
9 % among person use regimen prophylaxis 
24 % rr 0.4 ; 95 % ci 0.2-0 .9 . 
twelve person use prophylaxis report 
side effect fear possible side effect reason . 
risk malaria lower among person report use 
medical newsletter page 5 
volume 6 , number 11 april 25 , 1993 
time 7 % among person sometimes rarely 
use 15 % rr 0.5 ; 95 % ci .0 . 
risk malaria 
also lower among person consistently use insect repellent evening 
, compare rarely use repellent 15 % rr 0 ; 
upper 95 % confidence limit 1.2 . 
risk malaria associate 
failure window door screen wear long sleeve pants 
evening . 
result investigation , staff review personnel 
need use comply recommend malaria 
regimen . 
staff also emphasize need use personal protection 
measure make plan obtain 
provide window door screen personnel . 
report : u.s. embassy health unit , kampala , uganda ; office medical 
svc , dept state , washington , d.c. malaria br , div parasitic disease , 
national center infectious disease , cdc . 
editorial note : uganda , increase malaria among u.s. personnel 
attribute poor adherence recommend malaria 
regimen use personal protection measure period increase 
malaria transmission intensify chloroquine resistance sub-saharan 
africa . 
finding report underscore need provide initial 
continued counseling regard malaria prevention person live abroad 
area -- preventive measure also important 
short-term traveler area . 
mefloquine effective prophylaxis regimen africa 
area p. falciparum ; however , area 
e.g. , thailand , resistance mefloquine may limit effectiveness . 

africa , efficacy mefloquine , compare chloroquine alone , 
prevent infection p. falciparum 92 % 1 . 
mefloquine safe 
well tolerate give 250 mg per week 2-year period . 
risk 
serious adverse reaction possibly associate mefloquine prophylaxis 
e.g. , psychosis convulsion low i.e. , 1.3-1 .9 episode per 100,000 
user 2 , risk less severe adverse reaction e.g. , dizziness , 
gastrointestinal complaint , sleep disturbance similar 
antimalarial 1 . 
doxycycline similar prophylactic efficacy mefloquine , need 
daily dosing may reduce compliance effectiveness regimen 
3,4 . 
chloroquine alone effective prophylaxis area intense 
chloroquine resistance e.g. , southeast asia africa . 
africa , 
person take mefloquine doxycycline , chloroquine 
alternative , although less effective , regimen . 
chloroquine 
use malaria prevention area p. 
falciparum report . 
country-specific recommendation prevent malaria information 
medical newsletter page 6 
volume 6 , number 11 april 25 , 1993 
dosage precaution malaria regimen 
available health information international travel , 1992 i.e. , 
`` yellow book '' 5 24 hour day telephone fax , . 
reference 
1 . 
lobel ho , miani m , eng , et al. . 
long-term malaria prophylaxis weekly 
mefloquine peace corps volunteer : effective well tolerate regimen . 
lancet 1993 ; -51 . 
2 . 
world health organization . 
review central nervous system adverse event 
related antimalarial drug , mefloquine 1985-1990 . 
geneva : world health 
organization , 1991 ; publication . 
. 
3 . 
pang l , n , p. prophylactic treatment vivax 
falciparum malaria low-dose doxycycline . 
j infect dis 1988 ; -7 . 
4 . 
pang l , n , boudreau ef , p. doxycycline prophylaxis 
falciparum malaria . 
lancet 1987 ; -4 . 
5 . 
cdc . 
health information international travel , 1992 . 
atlanta : us 
department health human services , public health service , ; 
publication . 
cdc . 
medical newsletter page 7 
volume 6 , number 11 april 25 , 1993 
fda approval use new haemophilus b conjugate vaccine 
combined haemophilus b conjugate 
vaccine infant child 

source : mmwr 42 15 date : apr 23 , 1993 
haemophilus influenza type b hib conjugate vaccine 
recommend use infant since 1990 , routine use infant 
vaccination contribute substantial decline incidence hib 
disease united states 1-3 . 
vaccine diphtheria , tetanus , 
pertussis infancy childhood administer routinely 
united states since late 1940 associate greater 
90 % reduction morbidity mortality associate infection 
organism . 
increase number vaccine routinely 
recommend infant , high priority development combine 
vaccine allow simultaneous administration fewer separate 
injection . 
food drug administration fda recently license two new product 
vaccinate child disease : 1 haemophilus b 
conjugate vaccine tetanus toxoid conjugate , trademark , 
vaccination hib disease 2 combined diphtheria tetanus 
toxoid pertussis vaccine dtp hib conjugate vaccine 
trademark , combination vaccine formulate use 
vaccinate child diphtheria , tetanus , pertussis , hib disease . 
trademark 
march 30 , 1993 , fda approve new haemophilus b conjugate 
vaccine , toxoid conjugate , 
manufacture pasteur merieux serum et distribute 
trademark connaught laboratories , inc. swiftwater , pennsylvania . 

vaccine license use infant primary 
vaccination series administer age 2 , 4 , 6 month . 
previously 
unvaccinated infant 7-11 month age receive two dose 2 month 
apart . 
previously unvaccinated child 12-14 month age receive one 
dose . 
booster dose administer 15 month age recommend 
child . 
previously unvaccinated child month age receive 
single dose require booster . 
90 % infant receive 
primary vaccination series trademark consecutive dose 2 , 4 , 
6 month age develop geometric mean titer b 
polysaccharide antibody greater 1 4 . 
response similar 
infant receive recommend series previously license 
haemophilus b conjugate vaccine efficacy demonstrate 
prospective trial . 
two u.s. efficacy trial terminate early 
concomitant licensure haemophilus b conjugate vaccine 
medical newsletter page 8 
volume 6 , number 11 april 25 , 1993 
use infant 4 . 
study , case invasive hib disease 
detect approximately 6000 infant vaccinate . 

study suggest efficacy vaccine similar 
licensed hib vaccine . 
trademark 
march 30 , 1993 , fda approve combined diphtheria tetanus 
toxoid pertussis vaccine dtp haemophilus b conjugate 
vaccine . 
trademark , available biologicals pearl 
river , new york , combine two previously license product , dtp 
registered , manufacture lederle laboratories pearl river , new york 
haemophilus b conjugate vaccine registered , manufacture praxis 
biologics , inc. . 
rochester , new york . 
vaccine license use child age 2 year 
protection diphtheria , tetanus , pertussis , hib disease 
indication vaccination dtp vaccine haemophilus b conjugate 
vaccine coincide . 
base demonstration co higher antibody 
response component two vaccine , trademark 
expect provide protection hib , well diphtheria , tetanus , 
pertussis , equivalent already license formulation 
dtp haemophilus b vaccine . 
advisory committee immunization practices acip recommend 
infant receive primary series one licensed haemophilus b 
conjugate vaccine begin 2 month age booster dose age 12 - 
15 month 5 . 
acip also recommend infant receive 
primary series diphtheria tetanus toxoid pertussis vaccine 2 , 
4 , 6 , 15-18 month age , booster dose 4-6 year 6-8 . 

complete statement regard recommendation use trademark 
trademark develop . 
report : office vaccines research review , center biologics 
evaluation research , food drug administration . 
div immunization , 
national center prevention svcs ; meningitis special pathogen br , div 
bacterial disease , national center infectious disease , 
cdc . 
reference 
1 . 
adams wg , deaver ka , cochi sl , et al. . 
decline childhood haemophilus 
influenza type b hib disease hib vaccine era . 
jama 1993 ; -6 . 
2 . 
broadhurst le , erickson rl , kelley pw . 
decrease invasive haemophilus 
influenza disease u.s. army child , 1984 1991 . 
jama 
1993 ; -31 . 
3 . 
murphy tv , white ke , pastor p , et al. . 
decline incidence haemophilus 
influenza type b disease since introduction vaccination . 
jama 
medical newsletter page 9 
volume 6 , number 11 april 25 , 1993 
1993 ; -8 . 
4 . 
b , plotkin s. efficacy safety haemophilus influenza type 
b capsular protein conjugate vaccine . 
j 
1992 ; -62 . 
5 . 
acip . 
haemophilus b conjugate vaccine prevention haemophilus 
influenza type b disease among infant child two month age 
older : recommendation immunization practices advisory committee 
acip . 
mmwr 1991 ; 40 . 
. 
6 . 
acip . 
diphtheria , tetanus , pertussis -- recommendation vaccine use 
preventive measure : recommendation immunization practices 
advisory committee acip . 
mmwr 1991 ; 40 . 
. 
7 . 
acip . 
pertussis vaccination : acellular pertussis vaccine reinforce 
booster use -- supplementary acip statement : recommendation 
immunization practices advisory committee acip . 
mmwr 1992 ; 41 . 
. 
8 . 
acip . 
pertussis vaccination : acellular pertussis vaccine fourth 
fifth dose dtp series -- update supplementary acip statement : 
recommendation immunization practices advisory committee acip . 
mmwr 
1992 ; 41 . 
. 
use trade name commercial source identification 
imply endorsement public health service u.s. department 
health human services . 
medical newsletter page 10 
volume 6 , number 11 april 25 , 1993 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
dental news 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
international workshop explore oral manifestation 
hiv infection 
research digest 
write jody dove 
march 1993 
national institute dental research 
second international workshop oral manifestation hiv 
infection , hold january 3 san francisco , participant explore 
issue relate epidemiology , basic molecular virology , mucosal 
immunology , oral clinical presentation hiv infection . 
workshop organize dr. john greenspan dr. deborah 
greenspan department stomatology , school dentistry , university 
california , san francisco . 
international steering committee scientific 
program committee provide guidance . 
conference draw 260 scientist 39 country , include 
asia , africa , europe , central america , south america , well united 
states canada . 
support tor workshop provide national 
institute dental research , national cancer institute , national 
institute allergy infectious disease , nih office aids research , 
procter gamble company . 
among topic discuss : epidemiology hiv lesion ; ethic , 
professional responsibility , public policy ; occupational issue ; provision 
oral care hiv-positive population ; salivary hiv transmission 
mucosal immunity ; opportunistic infection ; pediatric hiv infection ; 
woman 's issue . 
recommendation 
recommendation emerge workshop define association 
appearance oral lesion rate progression hiv , 
establish universal terminology oral lesion , look 
effective treatment oral manifestation , expand molecular biology 
study understand relationship hiv infection common oral 
lesion , study effect hiv therapy oral lesion . 
epidemiology 
since first international workshop oral manifestations hiv 
infection convene five year ago , epidemiology hiv infection 
medical newsletter page 11 
volume 6 , number 11 april 25 , 1993 
radically change . 
1988 , hiv infection detect report largely 
homosexual bisexual male , intravenous drug user , hemophiliac . 
today , hiv infection see heterosexual male female 
child adolescent . 
predominant impact hiv infection feel africa , 
major increase infection rate see southeast asia well . 
five hundred thousand case report date region 
appear time . 
researcher continue document epidemiology oral lesion 
hairy candidiasis . 
also begin explore 
relationship specific oral lesion hiv disease progression 
prognosis . 
issue 
discussion social political implication hiv infection 
focus change public 's attitude aid retribution 
indiscriminate sexual behavior drug use . 
speaker also address health 
care delivery hiv-infected patient , need educate public 
aid , acquire . 
saliva salivary gland 
conference speaker describe transmission issue 
activity saliva , strength vary among different salivary 
secretion . 
whole saliva greater inhibitory effect submandibular 
secretion , turn greater inhibitory effect parotid 
secretion . 
research show least two mechanism responsible 
salivary inhibitory activity . 
attribute effect 
saliva 1 hiv saliva , may 
promote clearance virus prevent reach target cell , 2 
direct effect virus target cell . 
topic discuss manifestation salivary gland disease 
hiv-infected person current research oral mucosal immunity . 
pediatric issue 
pediatric aids recently emerge area intense interest . 

early accurate diagnosis proper treatment , life expectancy hiv - 
infected child triple . 
prevention transmission hiv 
mother child may possible many case , particularly mother 's 
know prior give birth . 
periodontal gingival tissue disease 
medical newsletter page 12 
volume 6 , number 11 april 25 , 1993 
oral health researcher continue explore periodontal disease 
gingivitis find individual hiv infection . 
recommendation make 
workshop include standardization terminology , refinement 
diagnostic marker , standardization study design , proper consideration 
confound variable result periodontal therapy . 
occupational treatment issue 
occupational issue surround treatment hiv-infected individual 
treatment render hiv-infected health care professional still command 
considerable attention . 
factor consideration include 
hiv testing , care provider transmission hiv infection 
reverse , use mainstream versus dedicated facility 
treatment hiv-infected patient . 
conference participant anticipate third international workshop 
oral manifestations hiv infection hold five year less . 
proceedings second workshop publish quintessence 
company late 1993 . 
--------- end part 1 ------------ 
-- 
internet : fax : +1 
bitnet : fidonet > 15 
amateur packet : 
